Waugh Jacob M, Lee Jane, Dake Michael D, Browne Dan
Revance Therapeutics Inc, Newark, CA, USA.
Methods Mol Biol. 2011;683:553-72. doi: 10.1007/978-1-60761-919-2_39.
Considerations in rational designs of CPP-based transcutaneous delivery systems are described. Impact of design considerations of nonclinical and clinical results are presented in detail.
阐述了基于细胞穿透肽的经皮给药系统合理设计中的考量因素。详细介绍了非临床和临床结果的设计考量因素的影响。